CIPO Patents = 2

EPO Patents = 3

Forward Citations = 4

Loading Chart...

2 inventors (with patents filed for the assignee):

Thomas N Chase (7 out of 28 patents)

Kathleen E Clarence-Smith (7 out of 32 patents)

7 patents: Sort by Forward Citations

1. 11813248 - NK-1 antagonist compositions and methods for use in treating depression (2023-11-14),

2. 11813247 - NK-1 antagonist compositions and methods for use in treating depression (2023-11-14),

3. 11547700 - Compositions and methods for treating synucleinopathies (2023-01-10),

4. 11318122 - Pharmaceutical combination and its use for treating synucleinopathties (2022-05-03),

5. 11266633 - NK-1 antagonist compositions and methods for use in treating depression (2022-03-08),

6. 11160809 - NK1-antagonist combination and method for treating synucleinopathies (2021-11-02),

7. 10799484 - Compositions and methods for treating synucleinopathies (2020-10-13),

Chase Therapeutics Corporation is a biopharmaceutical company focused on developing novel therapies for the treatment of neurodegenerative diseases. Our mission is to improve the lives of patients by advancing innovative therapies that target the underlying mechanisms of neurodegeneration. With a team of experienced researchers and clinicians, we are dedicated to transforming the treatment landscape for neurodegenerative disorders.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

7 Patents

#89 in Washington, DC

#89 in District of Columbia

#38,761 in US

Washington, DC, United States of America

Chase Therapeutics Corporation

Forward Citations = 4

2 inventors:

Thomas N Chase (7 out of 28 patents)

Kathleen E Clarence-Smith (7 out of 32 patents)

Please report any incorrect information to support@idiyas.com

2 patents (CIPO):

Please report any incorrect information to support@idiyas.com

3 patents (EPO):

Please report any incorrect information to support@idiyas.com